Tim Dyer
Fondateur chez ADDEX THERAPEUTICS LTD
Fortune : 1 M $ au 30/04/2024
Provenance du réseau au premier degré de Tim Dyer
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 27 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Tim Dyer via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chairman | |
| NEKTAR THERAPEUTICS | Pharmaceuticals: Major | Chairman Chief Operating Officer | |
| BIOGEN INC. | Pharmaceuticals: Major | Director of Finance/CFO | |
| VERNALIS | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Miscellaneous Commercial Services | Director/Board Member | |
Calibra Medical LLC
 Calibra Medical LLC Medical SpecialtiesHealth Technology Calibra Medical LLC develops and markets medical devices and technologies in the diabetes sector. Its products include finesse and insulin delivery devices. The company was founded by Daniel Hawkins and Clifton A. Alferness in 2004 and is headquartered in Wayne, PA. | Medical Specialties | Director/Board Member | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree | |
Synthes, Inc.
 Synthes, Inc. Medical SpecialtiesHealth Technology Synthes, Inc. engages in the development, production, and marketing of instruments, implants, as well as biomaterials for surgical fixation, correction, and regeneration of the human skeleton and its soft tissues. The company was founded in 1999 and is headquartered in Solothurn, Switzerland. | Medical Specialties | Director/Board Member | |
| FEINTOOL INTERNATIONAL HOLDING AG | Metal Fabrication | Chief Executive Officer | |
| University of Cambridge | College/University | Doctorate Degree Corporate Officer/Principal | |
Basel - SpA
 Basel - SpA MiscellaneousMiscellaneous Part of Smith & Nephew plc, Basel SpA is an Italian company that specializes in medicinal chemicals and botanical products. The company is based in Ravenna, Italy. Basel was acquired by Smith & Nephew plc on April 01, 1995 for $4.80 million. | Miscellaneous | Corporate Officer/Principal | |
| OREXO AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Axovan AG
 Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
| BASILEA PHARMACEUTICA AG | Pharmaceuticals: Major | Chairman | |
| University of London | College/University | Doctorate Degree Doctorate Degree | |
| INSEAD | College/University | Masters Business Admin | |
| University of Vermont | College/University | Doctorate Degree | |
Organon Pharma (UK) Ltd.
 Organon Pharma (UK) Ltd. Pharmaceuticals: MajorHealth Technology Organon Pharma (UK) Ltd. develops and manufactures pharmaceuticals. It offers osteoarthritis pain treatment Arcoxia, cardiovascular medication Cozaar, HIV drug Crixivan and asthma treatment Singulair. It operates a research center specializing in the development of central nervous system disorder such as Alzheimer's disease, depression, anxiety and migrane. The company was founded in 1953 and is headquartered in Hoddesdon, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer | |
| University of Geneva | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member Chairman | |
| University of Paris Jussieu | College/University | Doctorate Degree | |
Merck Serono SA
 Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
Roche Ltd.
 Roche Ltd. Financial ConglomeratesFinance Roche Ltd. provides investment services. | Financial Conglomerates | Corporate Officer/Principal | |
CRI Worldwide LLC
 CRI Worldwide LLC Miscellaneous Commercial ServicesCommercial Services CRI Worldwide LLC engages in the provision of inpatient and outpatient clinical research services. It specializes in inpatient and outpatient clinical trials ranging from phase I to IV focusing on pediatrics, adolescents, adults, and elderly in the areas of acute and chronic pain, attention deficit hyperactivity disorder, Alzheimer’s disease, atypical depression, back pain, bipolar disorder, cancer pain, diabetes, epilepsy, fibromyalgia, general anxiety disorder, hepatitis, major depressive disorder, manic depression, migraines/headaches, mild cognitive impairment. The company was founded by Howard A. Hassman in 2000 and is headquartered in Mt. Laurel, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
GlaxoSmithKline AG
 GlaxoSmithKline AG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AG is a Swiss company. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Urrma AG
 Urrma AG Pharmaceuticals: MajorHealth Technology Urrma AG is a Swiss pharmaceutical company that focuses on research and development, manufacturing, and marketing of pharmaceutical products. The private company is based in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Biogen International GmbH
 Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| TET Systems AG | Director/Board Member | ||
PharmaSens AG
 PharmaSens AG Medical SpecialtiesHealth Technology PharmaSens AG develops medical devices for diabetes care. The private company is based in Reinach, Switzerland. | Medical Specialties | Director/Board Member | |
| Pivalor AG | Chief Executive Officer | ||
| 4D MOLECULAR THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| CYTOMX THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman | |
Inflamalps SA
 Inflamalps SA Pharmaceuticals: MajorHealth Technology Inflamalps SA operates as a biopharmaceutical company. The firm focuses on developing topical treatments for inflammation-mediated diseases in ophthalmology and dermatology. The company was founded by Charles Woler, Vincent Mutel and Philippe Meuwly in August 2012 and is headquartered in Monthey, Switzerlands. | Pharmaceuticals: Major | Chief Executive Officer | |
| PLIANT THERAPEUTICS, INC. | Biotechnology | Chairman | |
Quintessa Investment Co. Ltd.
 Quintessa Investment Co. Ltd. Investment ManagersFinance Quintessa Investment acts as alternative investment manager. It is engaged in financial investment activities. The company was founded on January 13, 2011 and is headquartered in Seoul, South Korea. | Investment Managers | Private Equity Investor | |
pH Pharma Co., Ltd.
 pH Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology pH Pharma Co. Ltd. engages in the developing and manufacturing of bio-pharmaceuticals. Its products include php-303, php-201, ab-101, nuvesse, alpine and torpedo products. The company was founded by Ho Young Huh on September 22, 2015 and is headquartered in Seoul, South Korea. | Pharmaceuticals: Major | Chief Executive Officer | |
| EIDOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Metys Pharmaceuticals AG
 Metys Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Part of Novaremed AG, Metys Pharmaceuticals AG is a pharmaceutical company based in Basel, Switzerland. The Swiss company specializes in developing dimiracetam for the prevention of chemotherapy-induced neuropathic pain. The company was founded by Michael Scherz, who has been the CEO since incorporation. Metys Pharmaceuticals was acquired by Novaremed AG on September 07, 2021. | Pharmaceuticals: Major | Director/Board Member | |
| Healthcare & Humanity Foundation | Founder | ||
Peak Bio Co. Ltd.
 Peak Bio Co. Ltd. BiotechnologyHealth Technology Part of Peak Bio, Inc., Peak Bio Co. Ltd. is a South Korean clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and inflammation. Peak Bio's location is in Seongnam, South Korea. The company's lead product candidate, php-303, is a small molecule currently in phase II clinical study for the orphan disease alpha1 anti-trypsin deficiency. Peak Bio has successfully completed phase I trials, demonstrating dose-dependent pharmacokinetics and establishing a dose for upcoming clinical trials. The company's cancer platform includes novel payloads and antibody-drug-conjugates (ADC) to address unmet needs in cancer care. The company was founded in 2015, and the CEO is Ho Young Huh. Peak Bio Co. was acquired by Ignyte Acquisition Corp. on November 01, 2022 for $353.84 million. | Biotechnology | Chief Executive Officer | |
| PEAK BIO, INC. | Pharmaceuticals: Major | Chairman | |
MedXCell SA
 MedXCell SA BiotechnologyHealth Technology MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then. | Biotechnology | Director/Board Member |
Statistiques
Internationale
| Suisse | 20 |
| Etats-Unis | 18 |
| Royaume-Uni | 6 |
| France | 4 |
| Corée du Sud | 4 |
Sectorielle
| Health Technology | 34 |
| Consumer Services | 8 |
| Commercial Services | 4 |
| Finance | 3 |
| Producer Manufacturing | 2 |
Opérationnelle
| Director/Board Member | 172 |
| Corporate Officer/Principal | 70 |
| Independent Dir/Board Member | 31 |
| Chairman | 29 |
| Chief Executive Officer | 18 |
Relations les plus connectées
| Insiders | |
|---|---|
| Antoine Papiernik | 48 |
| Ho Young Huh | 32 |
| Bharatt Chowrira | 24 |
| Beat E. Lüthi | 23 |
| Jake Nunn | 23 |
| Graham Dixon | 18 |
| Ray Hill | 18 |
| Isaac Manke | 15 |
| Oleg Nodelman | 15 |
| Alexandra Goll | 14 |
| Vincent Lawton | 11 |
| Werner Henrich | 10 |
| André J. Müller | 10 |
| Roger G. Mills | 8 |
| Vincent Mutel | 8 |
